騰盛博藥(02137.HK):研究中之新冠病毒聯合療法續對Omicron中和活性
騰盛博藥-B(02137.HK)公佈,新的體外嵌合病毒實驗中和數據表明,公司正在研究的新型冠狀病毒聯合療法「安巴韋單抗/羅米司韋單抗聯合療法」(此前稱BRII-196/BRII-198聯合療法)保持對新型冠狀病毒變異病毒株Omicron的中和活性。
公司表示,該等數據增加更多證據,證明安巴韋單抗/羅米司韋單抗聯合療法,對世界衛生組織關注的主要新型冠狀病毒變異病毒株均保持活性,包括Delta及Delta Plus。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.